The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI.
Image enhancement
Magnetic resonance imaging
Neoplasm grading
Prostate-specific antigen
Prostatic neoplasms
Radical prostatectomy
Texture analysis
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
16
02
2019
accepted:
21
03
2019
pubmed:
1
4
2019
medline:
10
1
2020
entrez:
1
4
2019
Statut:
ppublish
Résumé
To determine if multiparametric MRI (mpMRI) derived filtration-histogram based texture analysis (TA) can differentiate between different Gleason scores (GS) and the D'Amico risk in prostate cancer. We retrospectively studied patients whose pre-operative 1.5T mpMRI had shown a visible tumour and who subsequently underwent radical prostatectomy (RP). Guided by tumour location from the histopathology report, we drew a region of interest around the dominant visible lesion on a single axial slice on the T2, Apparent Diffusion Coefficient (ADC) map and early arterial phase post-contrast T1 image. We then performed TA with a filtration-histogram software (TexRAD -Feedback Medical Ltd, Cambridge, UK). We correlated GS and D'Amico risk with texture using the Spearman's rank correlation test. We had 26 RP patients with an MR-visible tumour. Mean of positive pixels (MPP) on ADC showed a significant negative correlation with GS at coarse texture scales. MPP showed a significant negative correlation with GS without filtration and with medium filtration. MRI contrast texture without filtration showed a significant, negative correlation with D'Amico score. MR T2 texture showed a significant, negative correlation with the D'Amico risk, particularly at textures without filtration, medium texture scales and coarse texture scales. ADC map mpMRI TA correlated negatively with GS, and T2 and post-contrast images with the D'Amico risk score. These associations may allow for better assessment of disease prognosis and a non-invasive method of follow-up for patients on surveillance. Further, identifying clinically significant prostate cancer is essential to reduce harm from over-diagnosis and over-treatment.
Identifiants
pubmed: 30929224
doi: 10.1007/s11255-019-02134-0
pii: 10.1007/s11255-019-02134-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
817-824Subventions
Organisme : UK Department of Health National Institute of Health Research
ID : n/a
Organisme : UK Department of Health National Institute of Health Research
ID : n/a
Organisme : London North West Healthcare Charitable Fund
ID : n/a
Organisme : UCL Experimental Cancer Medicine Centre
ID : n/a
Commentaires et corrections
Type : ErratumIn
Références
N Engl J Med. 2001 May 3;344(18):1373-7
pubmed: 11333995
J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8
pubmed: 18801515
Radiology. 2008 Dec;249(3):900-8
pubmed: 19011187
Radiology. 2009 Feb;250(2):444-52
pubmed: 19164695
J Magn Reson Imaging. 2009 Aug;30(2):327-34
pubmed: 19629981
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7
pubmed: 19786982
J Clin Oncol. 2010 Jan 1;28(1):126-31
pubmed: 19917860
World J Urol. 2010 Dec;28(6):667-72
pubmed: 20623288
Radiology. 2010 Dec;257(3):715-23
pubmed: 20843992
BJU Int. 2011 May;107(9):1411-8
pubmed: 21044250
Eur Urol. 2011 Apr;59(4):477-94
pubmed: 21195536
Clin Radiol. 2012 Feb;67(2):157-64
pubmed: 21943720
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
Neurol Res Int. 2012;2012:195176
pubmed: 22203901
Eur Radiol. 2012 Apr;22(4):746-57
pubmed: 22322308
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Eur Radiol. 2013 Jul;23(7):2019-29
pubmed: 23494494
Cancer Imaging. 2013 Sep 23;13(3):400-6
pubmed: 24061266
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
Radiology. 2014 Apr;271(1):143-52
pubmed: 24475824
Radiology. 2014 Jul;272(1):100-12
pubmed: 24654970
Eur Radiol. 2015 Feb;25(2):523-32
pubmed: 25226842
Invest Radiol. 2015 Apr;50(4):239-45
pubmed: 25501017
Eur Radiol. 2015 Oct;25(10):2840-50
pubmed: 25991476
Int Urol Nephrol. 2016 Apr;48(4):529-33
pubmed: 26759330
Eur Radiol. 2017 Jun;27(6):2348-2358
pubmed: 27620864
Int J Mol Sci. 2017 Apr 12;18(4):null
pubmed: 28417929
Eur Radiol. 2017 Dec;27(12):5290-5298
pubmed: 28608163
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Breast J. 2019 May;25(3):373-380
pubmed: 29602210
J Magn Reson Imaging. 2018 Dec;48(6):1637-1647
pubmed: 30102441
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478